Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation
Vincent T. Ho(Dana-Farber Cancer Institute), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Shelly Carter(European Society for Blood and Marrow Transplantation), Paul J. Martin(European Society for Blood and Marrow Transplantation), Robert J. Soiffer(Dana-Farber Cancer Institute), Roberta Adams(Mayo Clinic Health System), James L.M. Ferrara(Icahn School of Medicine at Mount Sinai), Mary M. Horowitz(Medical College of Wisconsin), Corey Cutler(Dana-Farber Cancer Institute)
Cited by 458
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k